Pillars of growth
Heavy bet for R&D
as a future
growth engine
Heavy bet on R&D
as a future
growth engine
Biosimilars
A great growth opportunity for ROVI in a market that totals more than 1,000 million euros in Europe.
Pharmaceutical products
Diversified portfolio of innovative own and licensed products protected by patents.
Low Molecular Weight Heparin
ROVI's principal product, a low-molecular-weight heparin developed in-house.
CDMO
High production capacity with four the manufacturing plants for prefilled syringes and oral solid forms.
Rovi in figures
829.5 Mn€
Operatig revenuein 2023
420.2 Mn€
· 420.2 Mn € Specialty Pharmaceutical business Sales in 2023(+1% vs 2022)
64
countries
LMWH presence through strategic alliances with international partners
24.9 Mn€
R&D expenses in 2023 (+4% vs 2022)
409.3 Mn€
CDMO Sales in 2023 (+1% vs 2022)
42,85%
Porcentage of women on the Boards of Directors
Information for investors
Detailed information for investors and shareholders. All of ROVI’s information, results and figures presented clearly and transparently.
Last news on Rovi
25/02/2025
Last annual report
Annual report 2023
Last regular
public information
Executive Summary
